Sleep disorder and its correction for patients with discirculatory encephalopathy

Abstract

The paper presents a comprehensive clinical, neurological, psychodiagnostic and neurophysiological study results of the Valeo-Dorm Duo drug use for 30 patients (average age 46.9 ± 2.3 years) with initial stages of discirculatory encephalopathy to correct the symptoms of insomnia, anxiety and asthenic syndrome. The Valeo-Dorm Duo drug was taken for two months simultaneously with the basic therapy; there was a 14 days break between the months of admission. A comparative analysis with a control group (30 people) who received only basic symptomatic therapy is carried out. The study design includes a comprehensive examination of all patients before the start of therapy, one month and two months after the start of treatment. It is shown that the combined use of Relax capsules in the daytime and Sleep capsules in the evening complement each other's effects, influencing the different parts of insomnia pathogenesis. The effectiveness of Valeo-Dorm Duo drug appears as an improvement of subjective night sleep indicators, a decrease of daytime sleepiness, and a declined severity of anxiety manifestations and asthenia symptoms during the first month of therapy, while the stable positive dynamics maintain until the end of treatment. According to an objective night sleep assessment using polysomnography, by the end of the treatment course, patients taking Valeo-Dorm Duo had a statistically significant reduction of the falling asleep process duration and the length and percentage of the REM phase increased; the delta sleep and slow wave sleep episodes in general have become longer too; cyclic sleep organization has recovered; the total duration of sleep increased, what resulted in the high rates of the night sleep efficiency index.